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ABSTRACT Recent studies suggest that high-affinity
neuronal nicotinic acetylcholine receptors (nAChRs)
containing 4 and 2 subunits (42*) functionally
interact with G-protein-coupled dopamine (DA) D2
receptors in basal ganglia. We hypothesized that if a
functional interaction between these receptors exists,
then mice expressing an M2 point mutation (Leu9Ala)
rendering 4 nAChRs hypersensitive to ACh may ex-
hibit altered sensitivity to a D2-receptor agonist. When
challenged with the D2R agonist, quinpirole (0.5–10
mg/kg), Leu9Ala mice, but not wild-type (WT) litter-
mates, developed severe, reversible motor impairment
characterized by rigidity, catalepsy, akinesia, and tremor.
While striatal DA tissue content, baseline release, and
quinpirole-induced DA depletion did not differ be-
tween Leu9Ala and WT mice, quinpirole dramatically
increased activity of cholinergic striatal interneurons
only in mutant animals, as measured by increased c-Fos
expression in choline acetyltransferase (ChAT)-positive
interneurons. Highlighting the importance of the cho-
linergic system in this mouse model, inhibiting the
effects of ACh by blocking muscarinic receptors, or by
selectively activating hypersensitive nAChRs with nico-
tine, rescued motor symptoms. This novel mouse
model mimics the imbalance between striatal DA/ACh
function associated with severe motor impairment in
disorders such as Parkinson’s disease, and the data
suggest that a D2R–4*-nAChR functional interaction
regulates cholinergic interneuron activity.—Zhao-Shea,
R., Cohen, B. N., Just, H., McClure-Begley, T., White-
aker, P., Grady, S. R., Salminen, O., Gardner, P. D.,
Lester, H. A., Tapper, A. R. Dopamine D2-receptor
activation elicits akinesia, rigidity, catalepsy, and
tremor in mice expressing hypersensitive 4 nicotinic
receptors via a cholinergic-dependent mechanism.
FASEB J. 24, 49–57 (2010). www.fasebj.org
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Motor symptoms associated with Parkinson’s disease,
including bradykinesia, rigidity, and resting tremor, are a
consequence of the degeneration of dopaminergic neu-
rons in basal ganglia (1). Although many studies show
that loss of striatal dopamine (DA) release partially un-
derlies loss of motor control, the striatum also receives a
strong acetylcholine (ACh) stimulus (2, 3) from tonically
active large aspiny cholinergic interneurons (4, 5). Not
surprisingly, ACh neurotransmission is thought to play a
critical role in controlling voluntary movement. For ex-
ample, in patients with Parkinson’s disease, as DA levels in
striatum decrease, ACh levels increase, suggesting that a
DA/ACh imbalance may underlie motor symptoms (6, 7).
Early treatments focused on blocking ACh signaling with
muscarinic receptor antagonists. These drugs can relieve
symptoms; however, severe side effects vitiate treatment
(8). The mechanism of the striatal ACh increase remains
unknown, although an early hypothesis stated that loss of
DA near D2 receptors (D2Rs) on cholinergic interneurons
led to disinhibition of these neurons and thus to the
increased ACh release (9, 10). Contrary to this idea, DA
depletion in primates fails to increase cholinergic in-
terneuron pacemaker activity, indicating that another
mechanism must account for the increase in striatal
ACh (11, 12).
Neuronal nicotinic ACh receptors (nAChRs) are
ligand-gated cation channels that are activated by the
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endogenous neurotransmitter, ACh, as well as by the
psychoactive component of tobacco, nicotine (13). To
date, 12 mammalian nAChR subunits are known
(2–10 and 2–4). The majority of high-agonist-affinity
neuronal nAChR subtypes are heteromeric pentamers
consisting of  and  subunits, while a subset of lower
agonist affinity nAChRs are 7 homopentamers (14,
15). Both nicotine and ACh modulate striatal cholin-
ergic interneuron excitability. Activation of nAChRs by
nicotine in striatal slices inhibits pacemaker activity of
cholinergic interneurons. Conversely, nAChR antago-
nists increase burst firing of these neurons, although
the mechanism and nicotinic receptor subtypes in-
volved in interneuron modulation is unknown (16).
Interestingly, nAChR expression decreases in striatum
of patients with Parkinson’s disease, as well as in animal
models of the disease (17, 18), suggesting that a loss of
nAChRs may contribute to dysregulation of cholinergic
interneuron excitability.
Previously, it was shown that the D2R-D3R antagonist
raclopride increased striatal DA release in rat, and this
effect was blocked by dihydro--erythroidine (19), a
competitive antagonist selective for 2* nAChRs
(* represents subunits other than those indicated that
may be present in the heteropentameric receptors). In
addition, 42* nAChRs could be immunoprecipitated
with D2Rs in transiently transfected HEK cell mem-
branes, as well as striatal membranes, suggesting a
direct physical interaction between the receptors (19).
This is consistent with emerging evidence suggesting
that DA receptors may exist as heteromeric complexes
with ligand-gated ion channels (20). To explore a
functional interaction between D2-like receptors and
4* nAChRs, we challenged mice expressing hypersen-
sitive 4* nAChRs (21, 22) with the D2R agonist
quinpirole. We hypothesized that if a functional inter-
action between 4* nAChRs and D2Rs exists, then
activation of D2Rs in these animals would unmask this
interaction. Remarkably, D2R activation in mutant, but
not wild-type (WT), littermates elicited severe motor
impairment characterized by akinesia, rigidity, cata-
lepsy, and tremor.
MATERIALS AND METHODS
Mice
Male and female Leu9Ala homozygous and WT littermates
used in experiments were 8–20 wk of age and were housed
3–4 animals/cage until the start of each experiment.
Leu9Ala mice express 4 nAChR subunits that contain a
single-point mutation, a leucine residue mutated to an ala-
nine residue, within the putative pore forming transmem-
brane domain, M2, that renders nicotinic receptors contain-
ing the mutated subunit 50-fold more sensitive to nicotine
and ACh (22, 23). The genetic engineering and initial
characterization of these mice has been described previously
(22). Animals were derived from heterozygous  heterozy-
gous breeding pairs. Data presented are from Leu9Ala mice
that were backcrossed to C57Bl/6J mice 8 generations.
Because no significant gender differences were observed
between male and female Leu9Ala mice or WT littermates in
preliminary experiments, both genders were used. Animals
were kept on a standard 12-h light-dark cycle with lights on at
7:00 AM and off at 7:00 PM. The animals were given food and
water ad libitum. All experiments were conducted in accor-
dance with the guidelines for care and use of animals
provided by the National Institutes of Health, as well as with
an animal protocol approved by the Institutional Animal Care
and Use Committee of the University of Massachusetts Med-
ical School, the University of Colorado, and the California
Institute of Technology.
Drugs
Quinpirole hydrochloride (0.5–10 mg/kg), nicotine hydro-
gen bitartrate (0.03 mg/kg), and scopolamine hydrochloride
(1 mg/kg) were purchased from Sigma (St. Louis, MO, USA)
and dissolved in saline. Mice were injected i.p. at a volume of
5 l/g body weight.
Behavior analysis
Ambulation
Ambulation (locomotion) was recorded in a novel cage using
a cage rack photobeam system (San Diego Instruments, San
Diego, CA, USA). A single ambulatory event was measured as
disruption of 2 distinct light beams 10 cm apart. For locomo-
tion measurements, mice were injected with quinpirole (5
mg/kg) in their home cage and then placed in the activity
cage 60 min later. Locomotor activity was recorded over a
90-min period.
Rigidity
To measure rigidity, mice were suspended by their hind legs
from the side of a plexiglass cage. The latency to fall was
measured (24, 25).
Akinesia
To measure akinesia, mice were held by the tail with forepaws
resting on a flat surface. The number of forward steps taken
with both forelimbs was recorded during 30-s trials (24). Each
animal received 2 trials every 30 min for 3 h. The 2 trials were
averaged for each data point.
Tremor
Tremor was scored visually by using the following scale: 0 , no
tremor; 1, isolated twitches; 2, tremor with periods of calm; 3,
constant tremor (26). Tremor was scored during tail suspen-
sion.
Eye closure
Eye closure was visually scored using the following scale: 1,
eyes 1
4
closed; 2, eyes 1
2
closed; 3, eyes 3
4
closed, 4, completely
closed (27).
Catalepsy
Catalepsy was measured using the horizontal bar method:
Mice had their forepaws placed on a horizontal bar 5 cm
above a flat surface. Latency to move forepaws off the bar was
50 Vol. 24 January 2010 ZHAO-SHEA ET AL.The FASEB Journal  www.fasebj.org
measured. The cutoff for latency to move paws from the bar
was 3 min.
Tissue collection
Mice were heavily anesthetized and decapitated, and brains were
removed and placed on a glass plate over ice. The optic nerves,
olfactory bulbs, and cerebellum were removed and discarded.
The cortical hemispheres were spread apart and separated by
cutting the corpus callosum, followed by removal of the hip-
pocampi. The striata (caudate-putamennucleus accumbens)
were removed without the adjacent cortex.
[3H]-spiperone binding
Plastic tubes (1 ml) set in a 96-well format were used. Buffer
consisted of 50 mM HEPES, pH 7.5; 120 mM NaCl; 2 mM
CaCl2; 1 mM MgCl2; and 5 mM KCl. Final reaction volume
was 600 l, consisting of mouse striatal membranes prepared
as described previously (28) in buffer containing 2.0 nM
3H-spiperone, 20 M pargyline, 1 mM ascorbic acid, and 50
nM ketanserin (to prevent spiperone binding to 5-HT2 recep-
tors). For nonspecific binding assessment, 18 mM DA was
added to the reaction. For D2/D3- vs. D4-binding populations,
binding buffer was supplemented with 300 nM raclopride.
Reaction mixtures were incubated at room temperature for
1 h to reach equilibrium, then binding was terminated by
filtration at 4°C onto glass fiber filters previously soaked in
0.5% polyethylenimine, and washed with ice-cold buffer (6)
using an Inotech Cell Harvester (Inotech, Rockville, MD,
USA). Filters were dried overnight, and radioactivity was
measured in a 1450 MicroBeta scintillation counter after
addition of Optiphase Supermix scintillation cocktail (both
from Perkin Elmer Life and Analytical Sciences/Wallac Oy,
Turku, Finland). Protein levels were determined by the Lowry
method using BSA as standard.
Cannulation surgery
Mice were given a buprenorphine injection (0.05–0.1 mg/kg.
s.c.) for pain relief before the operation. Mice were anesthe-
tized under isoflurane anesthesia (induction 4.5%; mainte-
nance 1.5–2.5%) and implanted with guide cannulae
(CMA/7; CMA/Microdialysis, Stockholm, Sweden). Guide
cannulae were positioned at the dorsal striatum based on
coordinates from the Franklin and Paxinos (29) mouse brain
atlas. Relative to bregma, the coordinates were A/P  0.6,
L/M1.8, D/V	3.0. Cannulae were affixed to the skull
with dental cement and 2 stainless steel screws. Postopera-
tively, 8–12 h after the initial dose, mice received another
injection of buprenorphine (0.05–0.1 mg/kg, s.c.) to relieve
pain. Mice were allowed to recover for 5 d before the start
of the experiment.
In vivo microdialysis
At 
4 PM on the day before the experiment, a microdialysis
probe (CMA/7; 1.0-mm membrane, o.d. 0.24 mm; CMA,
Stockholm, Sweden) was inserted into the guide cannula, and
the probe was infused with a modified Ringer solution (147
mM NaCl, 1.2 mM CaCl2, 2.7 mM KCl, 1.0 mM MgCl2, and
0.04 mM ascorbic acid) at a flow rate of 0.5 l/min. In the
morning of the experiment day (
8 AM), the flow rate was
increased to 2.2 l/min, and after 1 h, the collection of actual
microdialysis samples (every 20 min, 44 l/sample) was
started. After completion of the experiments, the positions of
the probes were verified histologically by fixing coronal brain
sections on gelatin/chrome-alume coated slides.
High-performance liquid chromatography (HPLC)
The concentrations of DA, 3,4-dihydroxyphenylacetic acid
(DOPAC), and homovanillic acid (HVA) were determined by
HPLC with an electrochemical detector (Coulochem II; ESA,
Chelmsford, MA, USA) equipped with a model 5014B micro-
dialysis cell, a Pharmacia LKB model 2248 HPLC pump
(Pharmacia LKB, Uppsala, Sweden), and a pulse damper (SSI
LP-21; Scientific Systems, State College, PA, USA). The col-
umn (Spherisorb ODS2; 3 m, 4.6100 mm, Waters, Milford,
MA, USA) was kept at 40°C with a column heater (Croco-Cil,
Bordeaux, France). The mobile phase used consisted of 0.1 M
NaH2PO4 buffer, pH 4.0 (adjusted with 1.0 mM citric acid),
0.6–0.8 mM octanesulphonic acid, 12–15% methanol, and
1.2 mM EDTA. The flow rate of the mobile phase was 1.0
ml/min. The dialysate sample (35 l) was injected onto the
column with a CMA/200 autoinjector (CMA). DA was re-
duced with an amperometric detector (potential 	100 mV)
after being oxidized with a coulometric detector (300 mV);
DOPAC and HVA were also oxidized with the coulometric
detector. The chromatograms were recorded, and the peak
heights were analyzed using Azur 4.0 software (Datalys, Theix,
France).
Striatal DA content
The brain was removed from the skull and placed on a glass
plate over ice. Striata were isolated as described above. Striata
were weighed and stored at 	80°C until assayed. The striatal
concentrations of DA, DOPAC, and HVA were measured by
HPLC with electrochemical detection (described above) after
Sephadex G-10 gel chromatographic cleanup of samples as
described by Haikala (30). As a control, frontal cortex nor-
epinephrine content was measured. Monoamine and metab-
olite values were calculated as micrograms per gram wet
weight of tissue.
Preparation of striatal tissue sections
A separate group of mice was used for immunohistochemistry
experiments. Mice were anesthetized with sodium pentobar-
bital (200 mg/kg, i.p.) 90 min after saline or quinpirole
injection (5 mg/kg), and perfused transcardially with 10 ml
of 0.1 M phosphate-buffered saline (PBS) followed by 10 ml
of 4% paraformaldehyde (pH 7.4). Brains were removed and
postfixed for 2 h, and cryoprotected in 30% sucrose until
brains sank. Striatal serial sections (20 m, from bregma 1.1
to 0.60 mm) were cut by using a freezing microtome and
collected into 24-well tissue culture plates containing PBS.
Double immunofluorescence
Free-floating sections were washed with PBS 2  5 min on an
orbital shaker, and incubated in 0.4% Triton X-100 PBS
(PBST) for 2  2 min followed by 2% BSA/PBS for 30 min.
Sections were washed with PBS once and then incubated in a
cocktail of primary antibodies for choline acetyltransferase
(ChAT; monoclonal, 1:100, sc-55557; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA) and c-Fos (polyclonal, 1:400, sc-52;
Santa Cruz) in 2% BSA/PBS overnight at 4°C. The sections
were then washed with PBS 3  5 min followed by incubation
in secondary fluorescence labeled antibodies (goat anti-rabbit
Alexa Fluor® 488 and goat anti-mouse Alexa Fluor 594, 1:250;
Molecular Probes, Eugene, OR, USA) at room temperature in
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the dark for 2 h. After washing with PBS 5  5 min, sections
were mounted on slides using Vectashield® mounting me-
dium (Vector Laboratories, Burlingame, CA, USA).
Optical density measurements
The number of c-Fos positive neurons was counted under a
fluorescence microscope (Carl Zeiss, Oberkochen, Germany)
with an 20 objective using an unbiased approach. The area
of each imaged section was 0.42 0.32 mm 0.13 mm2. The
immunopositive counts from dorsal striatum were averaged
and scaled to provide a mean number of c-Fos positive
cells/mm2. ChAT-positive neurons were imaged with an 63
objective. Striatal ChAT-positive neurons were sparse and
displayed a soma size 20 m in diameter, consistent with
striatal cholinergic interneurons that make up 
1% of neu-
rons in striatum (31). The intensity of fluorescence was
quantified using a computer-associated image analyzer (Ax-
iovision 4.6; Carl Zeiss). Neurons were counted as signal
positive if intensities were 2-fold higher than that of the
average value of background (sections stained without pri-
mary antibodies). The percentage of c-Fos positive neurons
that were also ChAT positive was calculated.
Statistics
Behavioral data were analyzed via 1- or 2-way ANOVAs, as
indicated, with repeated measures as needed. For immuno-
histochemistry, data were analyzed with Student’s t test. Data
were analyzed using Origin 7.5 software (OriginLab Corp.,
Springfield, MA, USA). All values are expressed as means 
se. Values of P  0.05 were considered significant.
RESULTS
In initial behavioral tests of D2R activation in Leu9Ala
mice, we injected Leu9Ala homozygous animals with
the D2-like receptor agonist, quinpirole. Figure 1 illus-
trates the responses to D2-like receptor activation 1 h
after injection of 5 mg/kg quinpirole in WT and
Leu9Ala mice (Fig. 1). Leu9Ala mice developed rigid-
ity of the extremities, postural instability, and arched
back (Fig. 1D) compared to WT (Fig. 1C). In addition,
resting tremor was observed during the onset of motor
symptoms, but ceased once rigidity and akinesia be-
came severe. However, when mice were held by the tail,
the tremor was readily apparent for the duration of the
phenotype. In addition, Leu9Ala displayed clasped
fore- and hindlimbs (Fig. 1B) compared to WT (Fig.
1A). After quinpirole injection, Leu9Ala mice were
significantly hypoactive in a novel environment com-
pared to WT animals (Fig. 2A, average summed activity
over 30 min 55.910.2 in WT mice vs. 5.291.66 in
Leu9Ala homozygous mice; F1,1320.8, P0.001). In
the catalepsy test (see Materials and Methods),
Leu9Ala mice had a significantly greater latency to
remove their forepaws from an elevated horizontal bar
compared to WT mice after quinpirole exposure, indi-
cating catalepsy (Fig. 2B, 139.323.1 vs. 1.670.33 s,
respectively; F1,435.5, P0.01). To measure rigidity,
mice were subjected to a “grasping” test (Fig. 2C; see
Materials and Methods). After quinpirole injection,
Leu9Ala mice grasped the side of a cage significantly
longer than WT mice (42.86.1 vs. 1.250.25 s, respec-
tively; F1,646.2, P0.001). Together, these behavioral
data indicate that Leu9Ala mice develop severe akine-
sia, rigidity, and tremor after quinpirole injection.
Leu9Ala mice displayed this phenotype with quinpi-
role doses as low as 0.5 mg/kg, whereas doses as high as
10 mg/kg did not elicit symptoms in WT mice (data not
shown).
To determine the onset, severity, and duration of
akinesia, we quantified and recorded the number of
forward steps taken with both forelimbs in Leu9Ala
and WT littermates before and after quinpirole injec-
tion (Fig. 2D). Steps were measured during 30-s trials
(24) every 0.5 h over the course of 3 h following
quinpirole injection. Overall, quinpirole induced a
significant effect on the akinesia assay postinjection in
mutant (F6,213.98, P0.01) but not WT animals
(F6,210.66, NS). Post hoc analysis revealed a significant
effect of quinpirole in Leu9Ala mice 0.5, 1.0, and 1.5 h
after injection, but not after 2.0, 2.5, or 3.0 h, indicating
recovery from the drug. Similarly, quinpirole signifi-
cantly elicited a tremor over time in Leu9Ala but not
WT mice. The tremor became constant 
 1 h post-
quinpirole injection (F6,2125.1, P0.001). Again, post
hoc analysis revealed a significant effect of tremor 1.0,
1.5, 2.0, and 2.5 h after injection but no significant
Figure 1. The D2-like receptor agonist quinpirole elicits a
hypomotor phenotype in Leu9Ala but not WT mice. Photo-
graphs of WT (A, C) and Leu9Ala mice (B, D) 1 h after
quinpirole injection (5 mg/kg, i.p.). Note the clasped fore-
and hindlimbs in Leu9Ala mice compared to WT animals
(A, B). D2R activation elicits akinesia, posture instability, and
rigidity in Leu9Ala mice but not WT animals (compare C and
D). Also note the arched back in Leu9Ala mice. (WT mice
were held by the tail to prevent locomotion during photo; C.)
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effect after 3.0 h (Fig. 2E). A similar timeline occurred
for quinpirole-induced eyelid closure (Fig. 2F). Thus,
symptoms were reversible;
3 h postinjection, Leu9Ala
mice acted indistinguishably from WT.
To determine whether the difference in quinpirole
sensitivity between genotypes was due to compensatory
changes of D2-like receptor expression in Leu9Ala
mice, we measured D2R levels using radioligand bind-
ing. In striatum there was no significant change in
raclopride-sensitive (D2R) or -resistant (D4R) [
3H]spip-
erone binding between Leu9Ala homozygous and WT
mice. Raclopride-sensitive binding in WT striatum was
225  16 fmol/mg protein compared to 217  51
fmol/mg protein in Leu9Ala striatum. Raclopride-
resistant binding in WT striatum was 389 24 fmol/mg
protein compared to 412  34 fmol/mg protein in
Leu9Ala striatum (n5/genotype).
Because of the known role of D2R in inhibiting
DAergic neuronal activity (32), we measured total
striatal tissue DA content in both genotypes. No signif-
icant difference was observed in DA tissue content
(data not shown). To assay striatal DA release, we
utilized in vivo microdialysis and compared DA concen-
trations in WT and Leu9Ala mice at baseline and after
injections of quinpirole. Baseline DA release was not
significantly different between genotypes (26.74.3
and 25.35.1 fmol/sample in WT vs. Leu9Ala homozy-
gous mice; n11/genotype). Using in vivo microdialy-
sis, we compared striatal DA release in WT and mutant
mice challenged with 0.5 mg/kg quinpirole. Similar to
previous reports, quinpirole significantly reduced DA
concentrations in striatum (33). A maximal reduction
of DA release was observed 60 min after quinpirole
injection in both WT and Leu9Ala mice to 51.7  8.8
and 40.0  4.4% of baseline, respectively (Fig. 3A).
Repeated-measure 2-way ANOVA indicated no signifi-
cant difference of genotype on this effect of quinpirole.
In addition, no significant differences in the effect of
quinpirole were observed on DA metabolites HVA and
DOPAC between genotypes (Fig. 3B, C). Notably, the
parkinsonian phenotype was observed in Leu9Ala but
not WT mice in response to 0.5 mg/kg quinpirole in
these experiments (data not shown).
Recently, striatal cholinergic interneurons have re-
emerged as potential modulators of parkinsonian symp-
toms (34). To determine whether these neurons were
involved in the quinpirole-induced motor phenotype in
Leu9Ala mice, we challenged a separate group of WT
and Leu9Ala mice with quinpirole and examined c-Fos
immunoreactivity in ChAT-positive striatal neurons as a
gross measure of neuronal activation (35–37). In WT
mice, the percentage of ChAT, c-Fos-immunopositive
neurons was not altered by quinpirole exposure com-
pared to saline (Fig. 4A, B; 24.31.5 vs. 23.93.8%).
However, quinpirole did significantly decrease the
number of non-ChAT, c-Fos-immunopositive neurons
Figure 2. Behavioral analysis of motor symptoms in Leu9Ala mice. A) Total ambulation in a novel environment 1 h after i.p.
injection of quinpirole (5 mg/kg) in WT (left) or Leu9Ala homozygous mice (right). B) Catalepsy assay: latency to remove paws
from an elevated horizontal bar 1 h after i.p. injection of quinpirole in WT (left) or Leu9Ala homozygous mice (right).
C) Rigidity assay: time spent grasping (hanging) from the side of a cage 1 h after quinpirole injection in WT (left) or Leu9Ala
(right) mice. D) Akinesia assay: Number of forward steps taken with both forelimbs during 30-s trials after injection of quinpirole
in WT (solid squares) or Leu9Ala homozygous mice (open squares). Mice received saline at time 0. Each data point represents
the average of 2 trials/animal every 30 min postinjection. E) Tremor score (see Materials and Methods) at 30-min intervals after
quinpirole injection in WT and Leu9Ala mice. F) Closed-eye score in WT and Leu9Ala after saline (t0) or at 30-min intervals
after quinpirole injection. n  4–8 mice/test. **P0.01, ***P  0.001.
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by 32.6  4.7% compared to saline (P0.05; n24–30
slices, 3 mice/treatment, data not shown). In contrast
to the effects in WT mice, quinpirole induced a robust,
significant increase in the percentage of c-Fos, ChAT-
immunopositive striatal neurons in Leu9Ala mice com-
pared to saline (72.80.4 vs. 20.11.5%, respectively;
P0.001; Fig. 4A, B). In addition, quinpirole increased
the number of non-ChAT, c-Fos-immunopositive neu-
rons by 38.2 14.1% compared to saline, although this
was not statistically significant (P0.05; n25–30 slices,
3 mice/treatment, data not shown). Together, these data
suggest that, although quinpirole decreases DA release in
striatum in both genotypes, it increases cholinergic inter-
neuron activity more strongly in Leu9Ala than in WT
mice.
To determine whether muscarinic ACh actions play a
role in the striking akinesia induced by quinpirole in
Leu9Ala mice, we preinjected mice with either saline
or the muscarinic antagonist scopolamine 15 min be-
fore quinpirole injection. Scopolamine preinjection
effectively rescued the phenotype. Leu9Ala mice that
received a scopolamine injection before quinpirole
exhibited significantly greater ambulation compared to
saline-preinjected mice (Fig. 5A). At 30 min, summed
average ambulation was 128.7  25.8 with scopolamine
pretreatment compared to only 12  8.6 with saline
pretreatment (Fig. 5B; F1,641.7, P0.001).
Based on previous studies indicating that nicotine
can inhibit cholinergic interneuron activity (16), we
also selectively activated Leu9Ala 4* nAChRs with a
small dose of nicotine (0.030 mg/kg) in animals
already expressing the quinpirole-induced akinetic
phenotype. Nicotine produced a robust, significant
burst in locomotor activity compared to a saline
injection (Fig. 5C). Summed average ambulation
during the 30 min immediately after nicotine injec-
Figure 4. Quinpirole activates striatal cholinergic interneu-
rons in Leu9Ala homozygous mice. A) Representative im-
ages of cholinergic interneurons within dorsal striatal slices
immunostained to detect c-Fos (left, green) or ChAT (mid-
dle, red). Right column shows merged images. WT (top 2
rows) and Leu9Ala mice (bottom 2 rows) were perfused and
brains were harvested 90 min after injection of saline (top) or
5 mg/kg quinpirole (bottom). B) Bar graph presents per-
centage of ChAT-positive neurons that also express c-Fos after a saline (open bars) or quinpirole (filled bars) injection.
**P  0.01.
Figure 3. Striatal release of DA and its metabolites does not differ between WT and Leu9Ala mice in response to quinpirole.
A) Striatal DA release of awake behaving WT and Leu9Ala mice, as measured by in vivo microdialysis, at baseline and after
injection of 0.5 mg/kg quinpirole (arrow). Microdialysis samples were acquired every 20 min. B, C) DOPAC (B)and
homovanillic acid release (C) for WT and Leu9Ala homozygous mice at baseline and after quinpirole as in A. n  8–11
mice/genotype.
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tion was significantly greater than summed ambula-
tion after a saline injection (60.19.7 after nicotine
vs. 7.64 after saline injection; F1,1424.3, P0.001;
Fig. 5D).
DISCUSSION
Improved mouse models of voluntary motor disorders
such as Parkinson’s disease are critical in order to
obtain a better understanding of potential mechanisms
underlying motor symptoms. Here we describe a novel
pharmacologically reversible hypomotor phenotype in
mice expressing 4* nAChRs that are hypersensitive to
ACh. This phenotype is revealed by activating D2-like
receptors via challenging mutant animals with the
D2-like receptor agonist quinpirole. In Leu9Ala mice,
but not WT littermates, quinpirole elicited several
motor symptoms that are often associated with a DA-
depleted state, including akinesia, rigidity, catalepsy,
and tremor.
Although quinpirole induced a dramatic decrease in
striatal DA release, presumably via activation of inhibi-
tory D2 autoreceptors in DAergic neurons of the sub-
stantia nigra pars compacta (38, 39), the onset and
magnitude of this effect did not differ between
Leu9Ala mice and WT littermates. In addition, base-
line DA release and striatal tissue content also did not
differ between genotypes. This finding is surprising,
both because the motor symptoms often indicate a
DA-depleted state and because previous studies suggest
that there may be crosstalk between D2Rs and 42
nAChRs on presynaptic DAergic terminals (19).
If a decrease in striatal DA release alone cannot
account for the remarkable motor impairments char-
acterized in quinpirole-challenged Leu9Ala mice, then
what is the explanation? Our data suggest that the
mechanism involves striatal cholinergic interneurons.
After quinpirole injection, Leu9Ala, but not WT mice,
exhibited robust increases in c-Fos immunoreactivity in
ChAT-positive striatal neurons, indicating increased
activation of cholinergic interneurons. While quinpi-
role decreased the number of c-Fos-immunoreactive
noncholinergic neurons in dorsal striatum of WT mice,
the drug increased the number of c-Fos-immunoreac-
tive neurons in Leu9Ala mice, supporting the hypoth-
esis that ACh concentrations were increased in these
animals. Administration of the acetylcholinesterase in-
hibitor tacrine, or activation of muscarinic receptors by
a nonspecific muscarinic agonist, such as pilocarpine,
can increase the number of c-Fos-immunoreactive neu-
rons (40, 41) in dorsal striatum. Furthermore, blocking
muscarinic receptors rescued motor impairment. This
finding is significant because motor symptoms, like
those associated with Parkinson’s disease, are associated
with a DA/ACh imbalance (7, 42). As DA decreases and
motor symptoms progressively become more severe,
striatal ACh levels rise. Cholinergic interneurons ex-
press inhibitory D2Rs that, when DA levels decrease,
could disinhibit these interneurons (42–44). However,
recent data suggest that cholinergic disinhibition via
DA depletion alone does not account for increased
ACh release, but rather is explained by reduction of
muscarinic receptor (M4) autoreceptors (45). Our data
indicate that neuronal nAChRs and D2Rs may function-
ally interact to modulate ACh levels during DA deple-
tion.
While most studies in striatum have focused on the
role of neuronal nAChRs expressed on DAergic presyn-
aptic terminals and their facilitation of striatal DA
Figure 5. Muscarinic antagonism and nicotinic agonism reverses quinpirole-induced
motor phenotype. A) Leu9Ala homozygous animals were injected with the musca-
rinic antagonist scopolamine (1 mg/kg, i.p., open squares) or saline (solid squares)
15 min before challenge with quinpirole (5 mg/kg). Each data point represents 5
min total ambulation in a novel activity chamber, 1 h after quinpirole injection.
B) Summed average ambulatory activity for 30 min from the experiment in panel A.
C) Leu9Ala homozygous mice were injected with 5 mg/kg quinpirole. At 1 h
postinjection, when the motor phenotype was readily apparent, mice were injected
with saline (solid squares) or 0.030 mg/kg nicotine (open squares) and immediately
placed in activity chambers. D) Summed average ambulatory activity for 30 min from
the experiment in panel C. **P  0.01, ***P  0.001.
55D2R–4-nACHR INTERACTION: MOTOR SYMPTOMS IN KNOCK-IN MICE
release (46–49), less is known about the expression
and function of nAChRs in striatal neurons. Our data
suggest that 4* nAChRs contribute, directly or indi-
rectly, to regulating cholinergic interneuron excitabil-
ity. Application of nicotine in striatal slices inhibits
cholinergic interneurons and, conversely, blockade of
nAChRs with the nonspecific antagonist mecamylamine
increases burst firing (16). Consistent with this finding,
selective activation of 4* nAChRs with nicotine rescued
motor impairment in Leu9Ala mice, although we cannot
rule out that this rescue was solely due to silencing of
cholinergic interneurons, since nicotine would also be
predicted to increase striatal DA release (50). In addition,
some reports indicate that nAChRs are expressed in
fast-spiking GABAergic interneurons, which presumably
provide local inhibitory input onto cholinergic interneu-
rons (51, 52), as well as the more predominant medium
spiny neurons of striatum. Thus, activation of nAChRs on
these interneurons would be expected to reduce cholin-
ergic interneuron excitability. However, we find no evi-
dence that striatal GABAergic or cholinergic interneurons
express 4* nAChRs (unpublished results).
How could mice expressing a single-point mutation
that renders 4* nAChRs hypersensitive to agonist
exhibit such a dramatic behavioral phenotype when
challenged with a D2-like receptor agonist? One expla-
nation could be that mice expressing the Leu9Ala 4
mutation have compensatory increases in D2 autorecep-
tor expression in DAergic neurons. However, radioli-
gand binding uncovered no such compensation. In
addition, in vivo microdialysis revealed little difference
in D2-like receptor agonist-mediated DA release in
striatum. These data also suggest that a functional
interaction between 4* nAChRs and D2Rs is unlikely
to exist in DAergic neurons themselves. We cannot rule
out the possibility that D2R expression is altered in
cholinergic interneurons in Leu9Ala mice, but in-
creased expression would not be expected to yield
neuronal activation in response to a D2 agonist. Possibly
the mechanism of this interaction involves known ef-
fects of nAChR activation on the frequency depen-
dence of DA release from DAergic terminals; this would
escape detection in the dialysis data and must be studied with
time-resolved measurements (53, 54). Therefore, future ex-
periments utilizing slice electrophysiology and electrochem-
istry will focus on uncovering a potential functional interac-
tion between 4* nAChR and D2-like receptors that results,
perhaps indirectly, in modulation of striatal cholinergic
interneurons.
In summary, our data provide a novel, reversible,
genetic, and pharmacological mouse model that mimics
the striatal DA/ACh concentration imbalance associated
with severe motor impairment. Because this phenotype is
elicited by a D2R agonist in a mouse expressing hypersen-
sitive 4* nAChRs, these data also suggest that 4*
nAChRs and D2Rs may functionally interact to regulate
cholinergic interneuron activity.
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